{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"10050"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16","value":"17010"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"20740"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"21310"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"25450"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Week 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15. Serum total Ctrough was summarized by time and treatment group.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During the 12-week treatment period, participants receive a total of 5 SC doses of PF-06946860 Q3W.","id":"OG000","title":"PF-06946860 Q3W"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The analysis set included all randomized participants who received a dose of PF-06946860 and in whom at least 1 serum concentration value was reported.","reportingStatus":"POSTED","timeFrame":"Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15","title":"Serum Total Ctrough of PF-06946860","type":"SECONDARY","unitOfMeasure":"ng/mL"}